OncRef

Clinical Trial: NCT04637763

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Caribou Biosciences, Inc.
Information Provided By:Caribou Biosciences, Inc.
Last Update Posted:2026-10-19

Study Overview

Brief Summary

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Official Title

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Conditions

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma

Intervention / Treatment

  • Genetic: CB-010
  • Drug: Cyclophosphamide
  • Drug: Fludarabine

Other Study ID Numbers

  • CB10A

Start Date (Actual)

2021-05-26

Primary Completion Date (Actual)

2025-09-11

Study Completion Date (Estimated)

2026-12-31

Enrollment (Estimated)

72

Study Type

Interventional

Phase

Phase 1